N-甲基-N-硫代苯甲酰肼 | 21048-05-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-甲基-N-硫代苯甲酰肼
• 英文名称: N-methylbenzothiohydrazide
• 英文别名: N-Thiobenzoyl-N-methyl-hydrazin；α-Methyl-thiobenzhydrazid；N-methylbenzenecarbothiohydrazide
• CAS: 21048-05-5
• 化学式: C₈H₁₀N₂S
• 分子量: 166.247
• InChiKey: JJZFQYXZSXBTEC-UHFFFAOYSA-N

物化性质

• 熔点：
  89-91 ºC
• 沸点：
  267 ºC
• 密度：
  1.189
• 闪点：
  115 ºC

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  61.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-甲基-N-硫代苯甲酰肼 以 N,N-二甲基甲酰胺 为溶剂， 生成 5-{[(4-chloro-phenyl)-cyano-methylene]-hydrazino}-3-methyl-2-phenyl-[1,3,4]thiadiazolium betaine
  参考文献：
  名称：

  中离子1,3,4-噻二唑和1,3,4-三唑-2-苄叉肼

  摘要：

  描述了将1，1-二卤代-2，3-二氮杂1，3-二烯（IX）和（X）用于合成新的中性离子杂环（VI）和（VII）的用途。

  DOI：

  10.1039/c39760000439
• 作为产物：
  描述：

  tert-butyl 2-methyl-2-(phenylcarbonothioyl)hydrazinecarboxylate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 生成 N-甲基-N-硫代苯甲酰肼
  参考文献：
  名称：

  [EN] PROCESS FOR PREPARING BIS(THIOHYDRAZIDE AMIDES)
  [FR] PROCÉDÉ DE PRÉPARATION DE BIS(THIOHYDRAZIDE AMIDES)

  摘要：

  公开号：

  WO2009123704A3
• 作为试剂：
  描述：

  N,N'-二环己基碳二亚胺 在 二硫化碳 、 N-甲基-N-硫代苯甲酰肼 作用下， 生成 N,N'-二环己基硫脲
  参考文献：
  名称：

  中渗1,3,4-噻二唑的光化学裂解：机理观察

  摘要：

  为了理解中离子1,3,4-噻二唑的光致碎裂机理，已经研究了代表性成员的光化学，合成，亲核加成光反应，低温光解和量子产率计算。量子产率计算表明开环反应具有自猝灭性和单分子性，而定时间隔红外记录显示光解过程中形成了杂多烯。

  DOI：

  10.1016/s0040-4020(01)93787-1

文献信息

• Facile and Convenient Synthesis of N′1,N′3-Dialkyl-N′1,N′3-bis(arylcarbonothioyl)malonohydrazides via Propylphosphonic Anhydride Coupling
  作者：Shoujun Chen、Zhiqiang Xia、Jun Jiang、Lijun Sun、Noriaki Tatsuta、Keizo Koya、Junyi Zhang、Gary Bohnert

  DOI：10.1055/s-0034-1378664

  日期：——

  substituted malonic acids using propylphosphonic anhydride (T3P®) under very mild conditions has been developed. A facile and convenient synthetic method for the anticancer agent elesclomol and its analogues, N′1,N′3-dialkyl-N′1,N′3-bis(arylcarbonothioyl)malonohydrazides, by the direct coupling of N-alkyl-N-(substituted)benzothiohydrazides and substituted malonic acids using propylphosphonic anhydride (T3P®)

  专用于成业袁教授和有机化学研究所上海（CAS）的李昕戴教授在他们的90个之际个生日 抽象 一种抗癌剂伊利司莫及其类似物，容易且方便的合成方法Ñ ' 1，Ñ ' 3 -二烷基Ñ ' 1，Ñ ' 3双（arylcarbonothioyl）malonohydrazides，通过直接耦合Ñ -烷基- ñ - （取代的）benzothiohydrazides和使用丙基膦酸酐（T3P取代的丙二酸®）已经开发下非常温和的条件。 一种抗癌剂伊利司莫及其类似物，容易且方便的合成方法Ñ ' 1，Ñ ' 3 -二烷基Ñ ' 1，Ñ ' 3双（arylcarbonothioyl）malonohydrazides，通过直接耦合Ñ -烷基- ñ - （取代的）benzothiohydrazides和使用丙基膦酸酐（T3P取代的丙二酸®）已经开发下非常温和的条件。
• Taxol enhancer compounds
  申请人：Synta Pharmaceuticals Corp.

  公开号：US20030195258A1

  公开（公告）日：2003-10-16

  Disclosed is a compound represented by the Structural Formula (I): 1 Y is a covalent bond, a phenylene group or a substituted or unsubstituted straight chained hydrocarbyl group. In addition, Y, taken together with both >C═Z groups to which it is bonded, is a substituted or unsubstituted aromatic group. Preferably, Y is a covalent bond or —C(R 7 R 8 )—. R 1 and R 2 are independently an aryl group or a substituted aryl group, R 3 and R 4 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. R 5 -R 6 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. R 7 and R 8 are each independently —H, an aliphatic or substituted aliphatic group, or R 7 is —H and R 8 is a substituted or unsubstituted aryl group, or, R 7 and R 8 , taken together, are a C1-C6 substituted or unsubstituted alkylene group. Z is ═O or ═S. Also disclosed are pharmaceutical compositions comprising the compound of the present invention and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of treating a subject with cancer by administering to the subject a compound of Structural Formula (I) in combination with taxol or an analog of taxol.

  揭示的是一种由结构式（I）表示的化合物： Y是一个共价键，一个苯基团或一个取代或未取代的直链烃基团。此外，Y与其结合的两个>C═Z基团一起，是一个取代或未取代的芳香基团。优选地，Y是一个共价键或—C(R7R8)—。R1和R2分别是芳基或取代芳基，R3和R4分别是—H，一个脂肪基，一个取代的脂肪基，一个芳基或一个取代的芳基。R5-R6分别是—H，一个脂肪基，一个取代的脂肪基，一个芳基或一个取代的芳基。R7和R8各自独立地是—H，一个脂肪或取代的脂肪基，或者R7是—H，R8是一个取代或未取代的芳基，或者R7和R8一起是一个C1-C6取代或未取代的烷基基团。Z是═O或═S。还公开了包含本发明化合物的药物组合物以及药学上可接受的载体或稀释剂。还公开了一种通过向患有癌症的受试者投与结构式（I）的化合物联合紫杉醇或紫杉醇类似物来治疗患者的方法。
• Paclitaxel enhancer compounds
  申请人：Koya Keizo

  公开号：US09107955B2

  公开（公告）日：2015-08-18

  Disclosed is a compound represented by the Structural Formula (I): Y is a covalent bond, a phenylene group or a substituted or unsubstituted straight chained hydrocarbyl group. In addition, Y, taken together with both >C═Z groups to which it is bonded, is a substituted or unsubstituted aromatic group. Preferably, Y is a covalent bond or —C(R7R8)—. R1 and R2 are independently an aryl group or a substituted aryl group, R3 and R4 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. R5-R6 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. R7 and R8 are each independently —H, an aliphatic or substituted aliphatic group, or R7 is —H and R8 is a substituted or unsubstituted aryl group, or, R7 and R8, taken together, are a C2-C6 substituted or unsubstituted alkylene group. Z is ═O or ═S. Also disclosed are pharmaceutical compositions comprising the compound of the present invention and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of treating a subject with cancer by administering to the subject a compound of Structural Formula (I) in combination with Paclitaxel or an analog of Paclitaxel.

  本文披露的化合物由结构式(I)表示：Y是共价键，苯基或取代或未取代的直链烃基。此外，Y与其键合的两个>C═Z基团一起构成取代或未取代的芳香基团。优选情况下，Y是共价键或—C(R7R8)—。R1和R2独立地是芳基或取代芳基，R3和R4独立地是—H，脂肪基，取代脂肪基，芳基或取代芳基。R5-R6独立地是—H，脂肪基，取代脂肪基，芳基或取代芳基。R7和R8各自独立地是—H，脂肪或取代脂肪基，或者R7是—H且R8是取代或未取代的芳基，或者R7和R8一起构成C2-C6取代或未取代的烷基基团。Z是 ═O 或 ═S。此外，还披露了包含本发明化合物的药物组合物和药用载体或稀释剂。还披露了一种使用Paclitaxel或Paclitaxel的类似物与结构式(I)化合物联合给癌症患者治疗的方法。
• Synthesis of taxol enhancers
  申请人：Shionogi BioResearch Corp.

  公开号：US20030069225A1

  公开（公告）日：2003-04-10

  Disclosed is a method of preparing a thiohydrazide product compound from a hydrazide starting compound. The hydrazide starting compound is represented by Structural Formula (I): 1 The thiohydrazide product compound is represented by Structural Formula (II): 2 In Structural Formulas (I)-(II), R 1 and R 2 are independently an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or R 1 and R 2 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. When R 2 is an aryl group or a substituted aryl group, then R 5 is a hydrazine protecting group; and when R 2 is an aliphatic or substituted aliphatic group, then R 5 is —H or a hydrazine protecting group. R 10 is —H or a substituted or unsubstituted alkyl group. The method comprising the step of reacting the starting compound with a thionylating reagent.

  本发明涉及一种从一个酰肼起始化合物制备硫代酰肼产物化合物的方法。所述酰肼起始化合物由结构式（I）表示：1 所述硫代酰肼产物化合物由结构式（II）表示：2 在结构式（I）-（II）中，R1和R2分别独立地是脂肪基，取代的脂肪基，芳基或取代的芳基，或者R1和R2连同它们连接的碳和氮原子形成一个非芳杂环环，该杂环可以与一个芳环融合。当R2是芳基或取代的芳基时，R5是一个肼保护基；当R2是脂肪基或取代的脂肪基时，R5是-H或肼保护基。R10是-H或取代或未取代的烷基。所述方法包括将起始化合物与硫酰化试剂反应的步骤。
• Purification of bis (thiohydrazide amides)
  申请人：Chen Shoujun

  公开号：US20080146842A1

  公开（公告）日：2008-06-19

  Disclosed herein are methods of purifying a bis(thio-hydrazide amides) compounds of the following structural formula: wherein R 1 , R 2 , R 3 , R 4 , R 7 , R 8 , Z, and Y are defined herein.

  本文披露了一种纯化以下结构式的双(硫代肼酰胺)化合物的方法：其中R1、R2、R3、R4、R7、R8、Z和Y在此处被定义。